@article{amari:hal-04652518,
TITLE = {Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)},
AUTHOR = {Amari, Lyria and Tomasini, Pascale and Dantony, Emmanuelle and Rousseau-Bussac, Ga{\"e}lle and Ricordel, Charles and Bigay Game, Laurence and Arpin, Dominique and Morel, Hugues and Veillon, Remi and Justeau, Gr{\'e}goire and Huchot, Eric and Fournel, Pierre and Vergnen{\`e}gre, Alain and Bizeux, Acya and Subtil, Fabien and Clarisse, Benedicte and Decroisette, Chantal and Choua{\"i}d, Christos and Greillier, Laurent and Bylicki, Olivier},
URL = {https://hal.science/hal-04652518},
JOURNAL = {Lung Cancer},
PUBLISHER = {Elsevier},
VOLUME = {193},
PAGES = {107843},
YEAR = {2024},
DOI = {10.1016/j.lungcan.2024.107843},
KEYWORDS = {Non -small cell lung cancer ; Chemo-immunotherapy ; Antiangiogenic ; HRQOL ; Toxicity},
PDF = {https://hal.science/hal-04652518v1/file/1-s2.0-S0169500224003775-main.pdf},
HAL_ID = {hal-04652518},
HAL_VERSION = {v1},
}